Trophos

This page shows the latest Trophos news and features for those working in and with pharma, biotech and healthcare.

Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

Roche buys rare disease firm Trophos in €470m deal

Roche buys rare disease firm Trophos in 470m deal. Will take control of olesoxime for spinal muscular atrophy. ... Roche is paying 120m upfront for Marseilles-based Trophos, with another 350m promised in the form of milestone payments.
Christine Placet appointed CEO of Trophos

Trophos has promoted its chief financial officer Christine Placet to CEO, replacing Damian Marron. ... Prior to joining Trophos in 2004, Placet served as chief financial officer in several companies across various industries.
Actelion net revenue up 18 per cent for Q2

Actelion also confirmed it has obtained the option to purchase Trophos, a France-based clinical stage pharmaceutical company, for 10m. ... Trophos has a pipeline of new molecular entities in development for the motor neuron diseases amyotrophic lateral
Trophos SA Awarded $1.4mn research grant

Agence Nationale pour la Recherche (ANR), the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development. ... Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Deal Watch table for January 2015

Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.
Pharma deals during January 2015

A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

No results were found

Add my company

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...